ARK Genomic Revolution ETF vs Nuwellis Inc — how do they compare? ARK Genomic Revolution ETF trades at $44.27, while Nuwellis Inc trades at $1.43 (market cap $542.80K). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | NUWE | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $44.55 | $220.50 |
52-Week Low | $24.02 | $1.42 |
Market Cap | — | $542.80K |
Enterprise Value | — | -$1.27M |
Trailing returns across standard periods
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →